Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19
NCT07445971Phase 1Recruiting
- Sponsor
- ModeX Therapeutics
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Multispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MDX2301 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by ModeX Therapeutics. Primary endpoint: Adverse Events at 12 months. Started Mar 2026; status: recruiting.
02
Drugs
MDX2301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07445971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445971.